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Hypertrophic scarring is caused by an imbalance between extracellular matrix (ECM) protein deposition and degradation \[[@CR1]\]. There are many factors affecting surgical scarring such as healing of the wounds, tension, and the line of the scars. Prolonged redness and post-inflammatory pigmentation of the scar tissues cause patients to be concerned about the noticeability of scars, especially in aesthetic surgery such as lower blepharoplasty, face-lift, or breast augmentation. Apart from the use of advanced wound dressing products to accelerate wound healing, many methods are used to prevent scar formation. Pressure garments, taping, and silicone gel have been prescribed for scar prevention \[[@CR2]\]; however, these methods have not been prescribed for the reduction or prevention of post-inflammatory hyperpigmentation, which is a common problem in patients with Fitzpatrick type IV or V skin \[[@CR3]--[@CR5]\]. It has previously been shown that herbal extracts have various effects in scar-remodeling pathways and might have scar-reduction properties \[[@CR6], [@CR7]\]. The combined herbal extract gel (CHG) is a composition of *Allium cepa* (12% w/w), *Centella asiatica* (5% w/w), *Aloe vera* (4% w/w), *Phyllanthus emblica* (1.5% w/w), and *Tamarindus indica* (1.5% w/w) extract. This formulation was developed as it was believed that their synergistic effects would help in the prevention of scar development \[[@CR8], [@CR9]\].

Only one randomized control study has been done to evaluate the efficacy of CHG in preventing surgical scarring \[[@CR9]\]. Thus, the purpose of this study was to evaluate the efficacy of the CHG in the prevention of surgical scar formation.

Methods {#Sec2}
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Patients aged over 18 years, who were Fitzpatrick type III or IV skin, and had under gone bilaterally symmetrical surgical procedures at Siriraj Hospital (Bangkok, Thailand) were enrolled in the study. Patients with critical illnesses (such as systemic infections or hemodynamic instability), major-acute illnesses, or chronic medical illnesses that can affect wound healing (such as bleeding disorders, transplantation, diabetes, obesity, cancer, chronic renal failure, and hematologic diseases) were excluded from the study. Pregnant patients and patients with allergic reactions to CHG were also excluded from the study.

All patients were briefed on the study protocol. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

The CHG and placebo were prepared in identical containers. The placebo gel was a combination of water, acrylate, C10-30 alkyl acrylate crosspolymer, polysorbate 20, and fragrance, and was similar in color and consistency to that of the CHG. The containers were labeled A or B. The identity of the gels was kept blind to the evaluator (second investigator) and the patients.

One week after the sutures were removed, random cards were withdrawn for each site of the scars to indicate which containers (A or B) would be applied on the sites, CHG on one scar and placebo on another scar. Application of the gels was done twice daily, once in the morning and once in the evening.

During each follow-up visit, the scars were photographed and evaluated using Patient and Observer Scar Assessment Scale (POSAS) \[[@CR10]--[@CR13]\]. Evaluations were done on the 2nd, 4th, 8th, and 12th week after commencing application of the gels. The assessment consisted of the two numeric scales: the Patient Scar Assessment Scale (PSAS), which was completed by the patient, and the Observer Scar Assessment Scale (OSAS), which was completed by one observer \[[@CR11], [@CR14]\]. The median of the total score of the POSAS was analyzed using the Wilcoxon paired signed-rank test method. A *P* value of \<0.05 was considered to be statistically significant. All data were analyzed with SPSS software (SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.).

Results {#Sec3}
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Twenty patients with Fitzpatrick type III or IV skin, classified as beige to beige-with-brown tint skin color, were enrolled in this study; however, only 17 patients completed the follow-up period. There were 34 wounds evaluated and analyzed. The average age of the patients was 39.44 years and ranged from 18 to 64 years. Demographic data are shown in Table [1](#Tab1){ref-type="table"}. Most of the surgical procedures in our study involved excision of nevus at both arms. The other operations were intercostal drainage of median sternotomy at the subcostal area (2 cases) and mandibular osteotomy at both angles of the chin (1 case). The dimensions of the scars included in this study varied from 3 to 10 cm.Table 1Demographic dataDemographic data*n* (%)Sex (*N* = 17) Female13 (76)Operation (*N* = 20) Lower blepharoplasty5 (25) Excision (excision of mole and excision of lipoma)6 (30) Liposuction4 (20) Breast surgery2 (10) Others (ICD drainage of median sternotomy and mandibular osteotomy)3 (15)*ICD* intercostal drainage

The CHG-treated scars showed lower PSAS scores compared with the placebo group in color, stiffness, thickness, irregularity, and overall scores with statistical significance at 12 weeks' follow-up (*P* value 0.03, 0.04, 0.03, 0.04, and 0.02, respectively; Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). The scores in pain and itching in the CHG group did not significantly differ from the placebo group at 12 weeks (*P* value 0.72 and 0.33, respectively). The scars in the CHG group showed lower OSAS scores compared with the placebo group in pigmentation, thickness, and overall scores at 12 weeks (*P* value 0.04, 0.04, and 0.04, respectively). The OSAS scores in vascularity, relief, and pliability in the CHG group were significantly less than those in the placebo group at 8 weeks (*P* value 0.03, 0.04, and 0.04, respectively). No side effects were observed in either group. The efficacy of CHG compared to placebo gel is demonstrated in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}.Fig. 1Patient Scar Assessment Scale score comparison between combined herbal extracts gel (CHG) and placebo group at 2, 4, 8, and 12 weeks' follow-upFig. 2Observer Scar Assessment Scale score comparison between combined herbal extracts gel (CHG) and placebo group at 2, 4, 8, and 12 weeks' follow-upFig. 3A 30-year-old female patient underwent excision nevus at both arms. At 8 weeks' follow-up, PSAS for CHG and placebo groups were 15 and 21, respectively, and OSAS for CHG and placebo groups were 14 and 23, respectively. At 12 weeks' follow-up, PSAS for CHG and placebo groups were 12 and 19, respectively, and OSAS for CHG and placebo groups were 12 and 21, respectively. *CHG* combined herbal extracts gel, *OSAS* Observer Scar Assessment Scale, *PSAS* Patient Scar Assessment ScaleFig. 4A 40-year-old female patient underwent bilateral breast reduction. At 4 weeks' follow-up, PSAS scores for the CHG and placebo groups were 29 and 32, respectively, and OSAS scores for the CHG and placebo groups were 21 and 28, respectively. At 12 weeks' follow-up, PSAS scores for the CHG and placebo groups were 21 and 21, respectively, and OSAS scores for the CHG and placebo groups were 21 and 22, respectively. *CHG* combined herbal extracts gel, *OSAS* Observer Scar Assessment Scale, *PSAS* Patient Scar Assessment Scale
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Scarring is one factor that affects patient satisfaction with operation results. The longest period of wound healing is the maturation phase \[[@CR15]\]. In this phase, surgical scars are hypervascularized, raised, and hard for 2--3 months after the wound has healed. The patient will also feel itching and some pain during this period. If we can reduce or shorten these signs and symptoms, the patient will benefit. Patients with Fitzpatrick type III skin or above have a greater chance of developing post-inflammatory hyperpigmentation, hypertrophic scarring, and keloids than patients with Fitzpatrick type I and II skin \[[@CR3]\]. Many methods have been described for scar prevention, such as pressure garments, taping, and silicone gel sheets/ointment \[[@CR2]\]; however, these methods have not been described for controlling post-inflammatory hyperpigmentation and the other symptoms experienced during the maturation phase. Silicone is believed to improve scarring via wound hydration and increased static charge \[[@CR16]--[@CR18]\]. These mechanisms effectively decrease the stimulation of keratinocytes, reduce cytokine production, and inhibit excessive collagen synthesis \[[@CR18]\]. Silicone also helps to rearrange the collagen fibers during the wound healing process via the polarization between the silicone and skin \[[@CR18]\]. It has previously been demonstrated that silicone has benefits in scar reduction \[[@CR18]--[@CR21]\]. However, silicone gel sheets may not always be appropriate in warm climates \[[@CR22]\]. Patients may sometimes feel sticky after silicone therapy \[[@CR22]\]. The silicone in a gel preparation is easy to use when compared with conventional silicone gel sheeting \[[@CR23]\]. Combination of the silicone derivative with other active compounds, such as onion extract (which have various mechanisms), may also have synergistic effects in scar prevention \[[@CR6], [@CR24]\].

*Allium cepa* (onion) extract, the main component of CHG, is useful in reducing neoangiogenesis in hypertrophic scars and keloids, resulting in the clinical improvement of skin vascularity \[[@CR7], [@CR24]--[@CR27]\]. It shows an anti-inflammatory effect by inhibiting lipopolysaccharide-induced tumor-necrosis factor-alpha (TNF-α) production \[[@CR28]\]. It also induces MMP-1 expression which has a key role in ECM remodeling \[[@CR29]\]. Hosnuter et al. \[[@CR24]\] reported that onion extract could fade scar color and the most effective therapeutic results were produced when it was combined with silicone gel sheet treatment. Several scientific reports have documented that *Centella asiatica* has the ability to enhance wound healing. By treating with *Centella asiatica* extract, the maturation of the scar is stimulated by the production of type I collagen. The treatment also results in a marked decrease in the inflammatory reaction and myofibroblast production \[[@CR30], [@CR31]\]. Asiaticoside, the active ingredient of *Centella asiatica*, has an anti-scarring effect by decreasing the transforming growth factor beta-1 expression and enhancing the expression of inhibitory SMAD-7 \[[@CR30], [@CR32]\]. *Aloe vera* is widely used as a traditional herbal medicine in many countries and is effective in the treatment of wounds \[[@CR33]\]. Some studies have shown that *Aloe vera* extract increases the rate of healing by enhancing keratinocyte multiplication and migration, the expression of proliferation-related factors, and epidermis formation \[[@CR33], [@CR34]\]. The study by Vázquez et al. \[[@CR35]\] reported that *Aloe vera* could interrupt cyclooxygenase enzyme (COX) function and decrease the production of eicosanoid. Therefore, the combined extracts of *Allium cepa*, *Centella asiatic*a, and *Aloe vera* may encourage an anti-inflammatory effect. *Tamarindus indica* extract has alkaloid, saponin, and tannin. Alkaloid is known to assist in the epithelization of wound and chemotaxis in fibrosis \[[@CR36]\]. Saponin significantly stimulates angiogenesis by modifying the balance of protease/protease inhibitor secretion in human endothelial vascular cells \[[@CR36]--[@CR38]\]. *Phyllanthus emblica* extract has antioxidant potentials as well as antimicrobial activity which can be a good therapeutic agent for accelerating the wound healing process \[[@CR39], [@CR40]\]. Baek et al. \[[@CR41]\] reported efficacy of *Phyllanthus emblica* in the prevention of hyperpigmentation by inhibiting tyrosinase activity. *Tamarindus indica* extract and *Phyllanthus emblica* may, therefore, have an additive effect in reducing hyperpigmentation.

In the results of our study, the color, stiffness, irregularity, and overall scores in PSAS and pigmentation, thickness, and overall scores in OSAS of the CHG study group showed improved scores at 12 weeks. We concluded that the CHG might improve scar formation. The scars might have less chance to develop post-inflammatory hyper-pigmentation. In this study, we did not compare the CHG with any pure silicone product. Moreover, the sample size is quite small and there are many other variables that may affect the outcomes. Further studies with larger sample sizes and longer term follow-ups are needed to confirm the benefit of this product.

Conclusion {#Sec5}
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Combination of Herbal Extracts gel might be effective in the prevention of surgical scar formation. It has demonstrated good results, especially in improving scar appearance and scar hyperpigmentation.
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